Terms: = Lymphoma AND ATR, Q13535, 545, ENSG00000175054, MEC1, SCKL, SCKL1, FRP1
186 results:
1. Blocking Orai1 constitutive activity inhibits B-cell cancer migration and synergistically acts with drugs to reduce B-CLL cell survival.
Scaviner J; Bagacean C; Christian B; Renaudineau Y; Mignen O; Abdoul-Azize S
Eur J Pharmacol; 2024 May; 971():176515. PubMed ID: 38547958
[TBL] [Abstract] [Full Text] [Related]
2. Selectively targeting BCL6 using a small molecule inhibitor is a potential therapeutic strategy for ovarian cancer.
Wu M; Xie J; Xing Y; Zhang L; Chen H; Tang B; Zhou M; Lv S; Huang D; Jian S; Zhou C; Liu M; Guo W; Chen Y; Yi Z
Int J Biol Sci; 2024; 20(2):486-501. PubMed ID: 38169532
[TBL] [Abstract] [Full Text] [Related]
3. ALK signaling primes the DNA damage response sensitizing ALK-driven neuroblastoma to therapeutic atr inhibition.
Borenäs M; Umapathy G; Lind DE; Lai WY; Guan J; Johansson J; Jennische E; Schmidt A; Kurhe Y; Gabre JL; Aniszewska A; Strömberg A; Bemark M; Hall MN; Eynden JVD; Hallberg B; Palmer RH
Proc Natl Acad Sci U S A; 2024 Jan; 121(1):e2315242121. PubMed ID: 38154064
[TBL] [Abstract] [Full Text] [Related]
4. The atr inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib.
Sartori G; Tarantelli C; Spriano F; Gaudio E; Cascione L; Mascia M; Barreca M; Arribas AJ; Licenziato L; Golino G; Ferragamo A; Pileri S; Damia G; Zucca E; Stathis A; Politz O; Wengner AM; Bertoni F
Br J Haematol; 2024 Jan; 204(1):191-205. PubMed ID: 38011941
[TBL] [Abstract] [Full Text] [Related]
5. Prognostic Value of
Carlier T; Frécon G; Mateus D; Rizkallah M; Kraeber-Bodéré F; Kanoun S; Blanc-Durand P; Itti E; Le Gouill S; Casasnovas RO; Bodet-Milin C; Bailly C
J Nucl Med; 2024 Jan; 65(1):156-162. PubMed ID: 37945379
[TBL] [Abstract] [Full Text] [Related]
6. Targeting TP53 disruption in chronic lymphocytic leukemia: Current strategies and future directions.
Molica S; Tam C; Allsup D; Polliack A
Hematol Oncol; 2024 Jan; 42(1):e3238. PubMed ID: 37937506
[TBL] [Abstract] [Full Text] [Related]
7. CDC6, a key replication licensing factor, is overexpressed and confers poor prognosis in diffuse large B-cell lymphoma.
Shen M; Zhang Y; Tang L; Fu Q; Zhang J; Xu Y; Zeng H; Li Y
BMC Cancer; 2023 Oct; 23(1):978. PubMed ID: 37833632
[TBL] [Abstract] [Full Text] [Related]
8. Translational development of a novel BAFF-R CAR-T therapy targeting B-cell lymphoid malignancies.
Luo Y; Qie Y; Gadd ME; Manna A; Rivera-Valentin R; To T; Li S; Yassine F; Murthy HS; Dronca R; Kharfan-Dabaja MA; Qin H
Cancer Immunol Immunother; 2023 Dec; 72(12):4031-4047. PubMed ID: 37814001
[TBL] [Abstract] [Full Text] [Related]
9. TuBG1 promotes hepatocellular carcinoma via atr/P53-apoptosis and cycling pathways.
Zhang Y; Wang ZZ; Han AQ; Yang MY; Zhu LX; Pan FM; Wang Y
Hepatobiliary Pancreat Dis Int; 2024 Apr; 23(2):195-209. PubMed ID: 37806848
[TBL] [Abstract] [Full Text] [Related]
10. Lisocabtagene maraleucel for second-line relapsed or refractory large B-cell lymphoma: patient-reported outcomes from the PILOT study.
Gordon LI; Liu FF; Braverman J; Hoda D; Ghosh N; Hamadani M; Hildebrandt GC; Peng L; Guo S; Shi L; Sehgal A
Haematologica; 2024 Mar; 109(3):857-866. PubMed ID: 37646670
[TBL] [Abstract] [Full Text] [Related]
11. Enhanced efficacy of combined fluzoparib and chidamide targeting in natural killer/T-cell lymphoma.
Gong C; Wu J; Song W; Li H; Shi C; Gao Y; Shi Z; Li Z; Zhang M
Ann Hematol; 2023 Oct; 102(10):2845-2855. PubMed ID: 37500898
[TBL] [Abstract] [Full Text] [Related]
12. A review of recent advances in the novel therapeutic targets and immunotherapy for lung cancer.
Khadela A; Postwala H; Rana D; Dave H; Ranch K; Boddu SHS
Med Oncol; 2023 Apr; 40(5):152. PubMed ID: 37071269
[TBL] [Abstract] [Full Text] [Related]
13. Identification and validation of hub genes in CD5-positive diffuse large B-cell lymphoma.
Yang M; Niu X; Yang X; Sun Y; Su W; Zhang J; Wu Q; Wang Y; Zhang Q; Ji H
Exp Biol Med (Maywood); 2023 Sep; 248(17):1469-1478. PubMed ID: 36847415
[TBL] [Abstract] [Full Text] [Related]
14. Investigating centrifugal filtration of serum-based FTIR spectroscopy for the stratification of brain tumours.
Theakstone AG; Brennan PM; Jenkinson MD; Goodacre R; Baker MJ
PLoS One; 2023; 18(2):e0279669. PubMed ID: 36800340
[TBL] [Abstract] [Full Text] [Related]
15. [The Expression and Correlation of
Li Y; Liu XY; Cui GR; Kong XY; Yang L; Luo JM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Feb; 31(1):120-124. PubMed ID: 36765487
[TBL] [Abstract] [Full Text] [Related]
16. Polθ Inhibition: An Anticancer Therapy for HR-Deficient Tumours.
Barszczewska-Pietraszek G; Drzewiecka M; Czarny P; Skorski T; Śliwiński T
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613762
[TBL] [Abstract] [Full Text] [Related]
17. Impact of poverty and neighborhood opportunity on outcomes for children treated with CD19-directed CAR T-cell therapy.
Newman H; Li Y; Liu H; Myers RM; Tam V; DiNofia A; Wray L; Rheingold SR; Callahan C; White C; Baniewicz D; Winestone LE; Kadauke S; Diorio C; June CH; Getz KD; Aplenc R; Teachey DT; Maude SL; Grupp SA; Bona K; Leahy AB
Blood; 2023 Feb; 141(6):609-619. PubMed ID: 36351239
[TBL] [Abstract] [Full Text] [Related]
18. The risk of cancer in patients with primary Sjögren syndrome: a single-center study from Turkey.
Aslan B; Öğüt TS; Erbasan F; Dilbil M; Çelik E; Terzioğlu ME; Yazısız V
Turk J Med Sci; 2022 Jun; 52(3):587-595. PubMed ID: 36326315
[TBL] [Abstract] [Full Text] [Related]
19. Health Benefits and Cost-Effectiveness of Children's Oncology Group Breast Cancer Screening Guidelines for Chest-Irradiated Hodgkin lymphoma Survivors.
Wong FL; Lee JM; Leisenring WM; Neglia JP; Howell RM; Smith SA; Oeffinger KC; Moskowitz CS; Henderson TO; Mertens A; Nathan PC; Yasui Y; Landier W; Armstrong GT; Robison LL; Bhatia S
J Clin Oncol; 2023 Feb; 41(5):1046-1058. PubMed ID: 36265088
[TBL] [Abstract] [Full Text] [Related]
20. Identifying patients with malignant spinal cord compression (MSCC) near end of life who can benefit from palliative radiotherapy.
Rades D; Segedin B; Schild SE; Lomidze D; Veninga T; Cacicedo J
Radiat Oncol; 2022 Aug; 17(1):143. PubMed ID: 35978340
[TBL] [Abstract] [Full Text] [Related]
[Next]
